Roche releases new data on key research in haemophilia new drug Hemlizumab
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, Swisspharmaceutical(http://giant Roche has released new data on key research byof the new drug(http:// of haemophili
aAt the meeting, Roche presented a total of 21 summaries from its haemophilia program, including five oral reportsData from four key HAVEN clinical studies confirm the long-term safety, effectiveness and quality of life benefits of Hemlibra in patients with type A haemophiliacs who have or do not have factor VIII inhibitors in the bodyIn addition, Roche also published the first interimanalysis of the phase IIIb STASEY study
(http://, which strengthened the safety of patients with type A haemophilia type A (12 years of age) who were present in clinical studies of HAVEN 1on hemlibra
Hemlibra is a bispecific monoclonal antibody that combines the two proteins necessary to activate the natural coagulation cascade reaction and restore the natural clotting process , the coagulation factors IXa and X -- to restore the clotting process in patients with type A haemophiliacsIn clinical studies, Hemlibra has been shown to significantly reduce bleeding events and improve machine function To date, Hemlibra has been approved by more than 70 countries and more than 40 countries for the prevention or reduction of the frequency of haemorrhagic events for patients with type A haemophilia who exist in vivo (based on HAVEN 1 and HAVEN 2 studies) and do not exist (based on HAVEN 3 and HAVEN 4 studies) factor VIII inhibitors
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
